Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
Background: The target product profile (TPP) outlines the desired profile of a target product aimed at a particular disease and is used by companies to plan clinical development. Considering the increasing importance of health technology assessment (HTA) in informing reimbursement decisions, a robus...
Saved in:
Main Authors: | Ting Wang (Author), Neil McAuslane (Author), Wim G. Goettsch (Author), Hubert G. M. Leufkens (Author), Marie L. De Bruin (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
by: Ting Wang, et al.
Published: (2020) -
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
by: Hedi Schelleman, et al.
Published: (2015) -
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
by: Lourens T. Bloem, et al.
Published: (2021) -
Real World Data in Health Technology Assessment of Complex Health Technologies
by: Milou A. Hogervorst, et al.
Published: (2022) -
An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017-2018 using the OpERA methodology
by: Lawrence Liberti, et al.
Published: (2020)